Description

Clinical Evidence

• In preclinical studies, Ipamorelin showed robust GH release with minimal stimulation of ACTH or cortisol, distinguishing it from earlier GHRPs.
• Rodent studies indicate that Ipamorelin can accelerate tissue regeneration and improve lean body mass under GH-deficient conditions.
• Its short half-life (~2 hours) allows for precise timing of GH pulses, ideal for circadian or training-based hormone optimization research.
Ipamorelin is often combined with GHRH analogs like Sermorelin or CJC-1295 in research to amplify the GH response.

Potential Side Effects

Ipamorelin is considered one of the best-tolerated GH secretagogues, though mild side effects may occur in some research subjects:
• Temporary injection site irritation
• Lightheadedness or mild fatigue
• Rare: slight water retention or increased appetite (less than with GHRP-6 or GHRP-2)
Due to its receptor selectivity, Ipamorelin is less likely to cause gastric discomfort, prolactin spikes, or insulin interference.

Disclaimer

This compound is intended strictly for research purposes and is not approved for human or veterinary use. All performance and safety references are based on preclinical and investigational studies. It must be handled by qualified professionals in a controlled laboratory setting.